Cytomegalovirus-associated chorioretinitis after liver transplantation: Case report and review of the literature

Transplant Infectious Disease

Volumn 10, Issue 1, 2008, Pages 27-43

  Egli, A ^a   Bergamin, O ^b   Mullhaupt B ^b   Seebach, J D ^b   Mueller, N J ^b   Hirsch, H H ^a,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chorioretinitis; CMV late disease; Cytomegalovirus; Ganciclovir; Immune reconstitution inflammatory syndrome; Immune reconstitution syndrome; Liver transplantation; Resistance; Retinitis; Vitritis

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CIDOFOVIR; COTRIMOXAZOLE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; STEROID; TACROLIMUS; VALGANCICLOVIR; VIRUS ANTIGEN;

ADULT; ANAMNESIS; ARTHRALGIA; ARTICLE; CASE REPORT; CHORIORETINITIS; CLINICAL FEATURE; COLITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LEUKOPENIA; LIVER TRANSPLANTATION; MEDICAL LITERATURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINA DETACHMENT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VITRECTOMY;

ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER TRANSPLANTATION; MIDDLE AGED;

EID: 38649112913     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00285.x     Document Type: Article

References (122)

1. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992 166 : 1223 1227.
2. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997 349 : 1443 1445.
3. Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr., Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998 116 : 169 175.
4. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004 18 : 1615 1627.
5. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999 179 : 697 700.
6. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004 38 : 1159 1166.
7. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemotherapy 2006 57 : 167 170.
8. Singh N, Lortholary O, Alexander BD, et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005 80 : 1131 1133.
9. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis 2005 41 : 354 360.
10. Drachenberg CB, Papadimitriou JC, Mann D, Hirsch HH, Wali R, Ramos E. Negative impact of human leukocyte antigen matching in the outcome of polyomavirus nephropathy. Transplantation 2005 80 : 276 278.
11. Schaub S, Mayr M, Egli A, et al. Transient allograft dysfunction from immune reconstitution in a patient with polyoma BK-virus-associated nephropathy. Nephrol Dial Transplant 2007 22 : 2386 2390. Epub June 2, 2007.
12. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001 71 : 1287 1294.
13. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007 22 (Supp 8 72 82.
14. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005 5 : 1065 1070.
15. Erice A, Jordan MC, Chase BA, Fletcher C, Chinnock BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987 257 : 3082 3087.
16. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988 158 : 124 131.
17. Van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, The TH. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988 26 : 2531 2535.
18. Harbison MA, De Girolami PC, Jenkins RL, Hammer SM. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988 46 : 82 88.
19. Paya CV, Hermans PE, Wiesner RH, et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989 160 : 752 758.
20. Paya CV, Smith TF, Ludwig J, Hermans PE. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 1989 6 : 670 675.
21. Stratta RJ, Shaefer MS, Markins RS, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989 124 : 1443 1450.
22. Salt A, Sutehall G, Sargaison M, et al. Viral and Toxoplasma gondii infections in children after liver transplantation. J Clin Pathol 1990 43 : 63 67.
23. King SM, Petric M, Superina R, Graham N, Roberts EA. Cytomegalovirus infections in pediatric liver transplantation. Am J Dis Child 1990 144 : 1307 1310.
24. Saint-Vil D, Luks FI, Lebel P, et al. Infectious complications of pediatric liver transplantation. J Pediatr Surg 1991 26 : 908 913.
25. Delgado R, Lumbreras C, Alba G, et al. Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients. J Clin Microbiol 1992 30 : 1876 1878.
26. Mellon A, Shepherd RW, Faoagali JL, et al. Cytomegalovirus infection after liver transplantation in children. J Gastroenterol Hepatol 1993 8 : 540 544.
27. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993 18 : 185 195.
28. Kalicinski P, Kaminski A, Prokurat A, et al. Diagnosis and monitoring of cytomegalovirus infection after liver transplantation in children. Ann Transplant 1993 1 : 13 14.
29. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993 119 : 984 991.
30. Kizilisik TA, Preiksaitis JK, Kneteman NM. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis. Transplant Proc 1993 25 : 2282 2283.
31. Manez R, St George K, Linden P, et al. Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J Clin Microbiol 1994 32 : 2655 2659.
32. Patel R, Smith TF, Espy M, et al. Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol 1994 32 : 1431 1434.
33. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994 58 : 779 785.
34. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994 120 : 375 381.
35. Snydman DR, Werner BG, Dougherty NN, et al. A further analysis of the use of cytomegalovirus immune globulin prophylaxis in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplant CMVIG-Study Group. Transplant Proc 1994 26 (5 Supp 1 23 27.
36. Singh N, Mieles L, Yu VL, Starzl TE. Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506? Dig Dis Sci 1994 39 : 15 18.
37. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994 170 : 644 652.
38. Drouet E, Colimon R, Michelson S, et al. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation. J Clin Microbiol 1995 33 : 389 394.
39. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. Transplantation 1995 59 : 31 40.
40. Mor E, Meyers BR, Yagmur O, et al. High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation. Transpl Int 1995 8 : 152 156.
41. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995 60 : 1357 1360.
42. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirs disease in liver transplantation. J Infect Dis 1995 171 : 1014 1018.
43. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995 346 : 69 74.
44. Mutimer D, Matyi-Toth A, Elias E, et al. Quantitation of cytomegalovirus in the blood of liver transplant recipients. Liver Transpl Surg 1995 1 : 395 400.
45. Falagas ME, Snydman DR, George MJ, et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center For Liver Transplantation CMVIG Study Group. Transplantation 1996 61 : 1716 1720.
46. Manez R, Kusne S, Rinaldo C, et al. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J Infect Dis 1996 173 : 1072 1076.
47. Badley AD, Patel R, Portela DF, et al. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. J Infect Dis 1996 173 : 446 449.
48. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusion. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996 23 : 292 297.
49. Raakow R, Bechstein WO, Kling N, et al. The importance of late infections for the long-term outcome after liver transplantation. Transpl Int 1996 9 : S155 S156.
50. McVicar JP, Kowdley KV, Emond JJ, et al. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. Clin Transplant 1997 11 : 328 333.
51. Gavalda J, de Otero J, Murio E, et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transpl Int 1997 10 : 462 465.
52. Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997 11 : 432 437.
53. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997 64 : 66 73.
54. Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997 64 : 1614 1617.
55. Mutimer D, Matyi-Toth A, Elias E, O'Donnell K, Stalhandske P. Patterns of viremia in liver transplant recipients with symptomatic cytomegalovirus infection. Transplantation 1997 63 : 68 73.
56. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997 350 : 1729 1733.
57. King SM, Superina R, Andrews SW, et al. Randomized comparison of ganciclovir plus intravenous immune globuline (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 1997 25 : 1173 1179.
58. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997 25 : 1344 1349.
59. Papanicolaou GA, Meyers BR, Fuchs SW, et al. Infectious ocular complications in orthotopic liver transplant patients. Clin Infect Dis 1997 24 : 1172 1177.
60. Ng P, McCluskey P, McCaughan G, Glanville A, MacDonald P, Keogh A. Ocular complications of heart, lung, and liver transplantation. Br J Ophthalmol 1998 82 : 423 428.
61. Langrehr JM, Glanemann M, Guckelberger O, et al. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation. Clin Transplant 1998 12 : 303 312.
62. Turgeon N, Fishman JA, Basgoz N, et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998 66 : 1780 1786.
63. Falagas ME, Paya CV, Ruthazer R, et al. Significance of cytomegalovirus for long term survivial after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998 66 : 1020 1028.
64. Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998 65 : 1477 1481.
65. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998 65 : 180 187.
66. Paterson DL, Singh N, Panebianco A, et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998 66 : 593 598.
67. de Otero J, Gavalda J, Murio E, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998 26 : 865 870.
68. Barkholt L, Lewensohn-Fuchs I, Ericzon BG, Tyden G, Andersson J. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis 1999 1 : 89 97.
69. Turgeon N, Fishman JA, Doran M, et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transpl Infect Dis 2000 2 : 2 10.
70. Singh N, Paterson DL, Gayowski T, Wagener MM, Merino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000 70 : 717 722.
71. Emery VC, Cope AV, Sabin CA, et al. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. J Infect Dis 2000 182 : 1610 1615.
72. Aw MM, Murugasu B, Tan AW, Seah CC, Balakrishnan V, Yap HK. Quantitation of peripheral blood cytomegalovirus DNA for monitoring recurrent cytomegalovirus retinitis in pediatric solid organ transplant recipients. Pediatr Transplant 2000 4 : 100 106.
73. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000 2 : 112 117.
74. Künzle N, Petignat C, Francioli P, et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transpl Infect Dis 2000 2 : 118 126.
75. Lohmann R, Langrehr JM, Klupp J, et al. Infectious complications after orthotropic liver transplantation with different immunosuppressive induction regimens. Transplant Proc 2000 32 : 537 538.
76. Fischer L, Sterneck M, Gahlemann CG, Malago M, Rogiers X, Broelsche CE. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathiophrine in primary liver transplant recipients. Transplant Proc 2000 32 : 2125 2127.
77. Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001 71 : 224 229.
78. Rayes N, Seehofer D, Schmidt CA, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001 72 : 881 885.
79. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001 184 : 1461 1464.
80. Snydman DR, Falagas ME, Avery R, et al. Use of combination cytomegalovirus immune globuline plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001 33 : 2571 2575.
81. Fan J, Ma W-H, Qian J, et al. Cytomegalovirus infection in liver transplant recipients. Hepatobiliary Pancreas Dis Int 2002 1 : 30 32.
82. Norris S, Kosar Y, Donaldson N, et al. Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection. Transplantation 2002 74 : 527 531.
83. Daly JS, Kopasz A, Anandakrishnan R, et al. Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients. Am J Transplant 2002 2 : 955 958.
84. Torre-Cisneros J, Madueno JA, Herrero C, et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 2002 8 : 773 780.
85. Piiparinen H, Höckerstedt K, Lappalainen M, Suni J, Lautenschlager I. Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients. J Clin Microbiol 2002 40 : 2945 2952.
86. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitic C. Liver Transpl 2002 8 : 362 369.
87. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002 185 : 854 860.
88. Oldakowska-Jedynak U, Niewczas M, Ziolkowski DJ, et al. Cytomegalovirus infection as a common complication following liver transplantation. Transplant Proc 2003 35 : 2295 2297.
89. Singhal S, Khan OA, Bramble RA, Mutimer DJ. Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies. J Infect 2003 47 : 104 109.
90. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003 187 : 1801 1808.
91. Shibolet O, Y Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003 16 : 861 865.
92. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004 78 : 1390 1396.
93. Freeman R, Paya CV, Peskovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004 78 : 1765 1773.
94. Millar AJW, Spearman W, McCulloch M, et al. Liver transplantation for children - the Red Cross Children's Hospital experience. Pediatr Transplant 2004 8 : 136 144.
95. Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004 10 : 728 733.
96. Winston DJ, Busuttil RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004 77 : 305 308.
97. Singh N, Gayowski T, Wagener MM, Zeevi A. T-helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections. Transpl Infect Dis 2004 6 : 93 96.
98. Galvan Ramirez ML, Castillo-de-Leon Y, Espinoza-Oliva M, et al. Acute infection of Toxoplasma gondii and cytomegalovirus reactivation in a pediatric patient receiving liver transplant. Transpl Infect Dis 2006 8 : 233 236.
99. Lin C-C, Chuang F-R, Lee CH, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005 11 : 1258 1264.
100. Shah T, Lai WK, Mutimer D. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus seropositive donors. Transpl Infect Dis 2005 7 : 57 62.
101. Gruttadauria S, Vasta F, Mandala L, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005 37 : 2611 2613.
102. Singh N, Wannstead C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005 11 : 700 704.
103. Seehofer D, Rayes N, Neumann UP, et al. Changing impact of cytomegalovirus in liver transplantation - a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis. Transpl Int 2005 18 : 941 948.
104. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005 79 : 85 90.
105. Akamatsu N, Sugawara Y, Kaneko J, Kishi Y, Makuuchi M. Risk factors of cytomegalovirus infection after living donor liver transplantation. Hepatogastroenterology 2005 52 : 197 199.
106. Martin-Davila P, Fortun J, Gutierrez C, et al. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value. J Clin Virol 2005 33 : 138 144.
107. Mengelle C, Abravanel-Legrand F, Kamar N, et al. Monitoring human cytomegalovirus (HCMV) in HCMV-seropositive orthotopic liver-transplant recipients by means of quantitative real-time polymerase chain reaction. Exp Clin Transplant 2006 4 : 537 543.
108. Lautenschlager I, Halme L, Hockerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infections of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006 8 : 21 30.
109. Hellinger WC, Bonatti H, Machicao VI, et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clin Proc 2006 81 : 1029 1033.
110. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006 12 : 112 116.
111. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006 81 : 1645 1652.
112. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc 2006 38 : 1922 1923.
113. Allice T, Enrietto M, Pittaluga F, et al. Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: comparison with end-point PCR and pp65 antigen test. J Med Virol 2006 78 : 915 922.
114. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007 195 : 633 644.
115. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005 201 : 1031 1036.
116. Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007 7 : 1997 2005.
117. Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005 40 : 1756 1761.
118. Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001 22 : 279 287.
119. Stone SF, Price P, Tay-Kearney ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002 185 : 1813 1817.
120. Hsieh SM, Pan SC, Hung CC, Tsai HC, Chen MY, Chang SC. Association between cytomegalovirus-specific reactivity of T-cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. J Infect Dis 2001 184 : 1386 1391.
121. Jacobson MA, Maecker HT, Orr PL, et al. Results of a cytomegalovirus (CMV)-specific CD8+/Interferon-g+cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J Infect Dis 2004 189 : 1362 1373.
122. Mutimer HP, Akatsuka Y, Manley T, et al. Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T-cell response. J Infect Dis 2002 186 : 701 705.